Trastuzumab 440 mg Injection: Product Guide, Uses, Strength, Storage & Procurement Information

Trastuzumab 440 mg Injection is a prescription monoclonal antibody medicine used in the treatment of certain HER2-positive cancers. Trastuzumab targets the HER2 protein, which can promote the growth of cancer cells when present at elevated levels. The medicine is administered by intravenous infusion under the supervision of qualified healthcare professionals.

For hospitals, oncology centers, specialty pharmacies, distributors, and authorized pharmaceutical procurement organizations, understanding the product strength, storage requirements, handling considerations, and documentation requirements is important when sourcing Trastuzumab 440 mg Injection internationally.

What Is Trastuzumab 440 mg Injection?

Trastuzumab is a recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). A 440 mg presentation is supplied as a lyophilized powder in a vial for preparation before intravenous administration. The FDA labeling for Herceptin identifies the 440 mg presentation as lyophilized powder per vial.

The appropriate product should be selected according to the prescribing information, regulatory requirements of the destination country, and the treating physician's clinical decision.

Trastuzumab 440 mg Uses

Trastuzumab is used for specific HER2-positive cancer indications, including certain forms of breast cancer and gastric or gastroesophageal junction cancer, depending on the approved product labeling and treatment setting.

Before treatment, HER2 status is generally assessed using an appropriate validated diagnostic method. Treatment decisions, dosing schedules, combination therapy, and duration of treatment should be determined by an oncologist according to the patient's condition and applicable prescribing information.

Trastuzumab is not intended for self-administration or routine retail use. It is administered as an intravenous infusion by trained healthcare professionals.

Trastuzumab 440 mg Strength & Presentation

Active ingredient: Trastuzumab

Strength: 440 mg per vial

Dosage form: Lyophilized powder for solution

Route: Intravenous infusion

Therapeutic category: HER2-targeted monoclonal antibody

The reference FDA labeling describes the 440 mg vial as a lyophilized sterile powder.

Because trastuzumab products can differ by manufacturer, brand, formulation, regulatory approval, and presentation, buyers should verify the exact product specification, manufacturer information, batch details, expiry date, and applicable regulatory documentation before procurement.

Trastuzumab 440 mg Storage Requirements

Proper cold-chain handling is essential for maintaining product quality. The FDA labeling for Herceptin states that unopened vials are stored at 2°C to 8°C (36°F to 46°F) and should not be used after the stated expiration date.

After reconstitution, storage conditions and allowable use periods depend on the diluent and product-specific instructions. The FDA reference labeling specifies refrigerated storage at 2°C–8°C for reconstituted product and provides specific stability limits.

For international pharmaceutical procurement, buyers should therefore consider temperature-controlled transportation, appropriate packaging, shipment monitoring, and documented cold-chain handling.

Procurement of Trastuzumab 440 mg Injection

Hospitals, distributors, oncology pharmacies, and qualified pharmaceutical buyers looking to source Trastuzumab 440 mg Injection from India should verify product availability, manufacturer or marketing authorization details, batch number, expiry, packaging, applicable certificates, and destination-country import requirements.

At Cordium Pharmaceuticals Pvt Ltd, procurement enquiries can be submitted for international pharmaceutical supply and export requirements. Buyers can provide the required quantity, destination country, preferred product specification, and delivery requirements so that availability and commercial terms can be evaluated.

International procurement may require documentation such as commercial invoices, packing lists, product certificates, shipping documentation, and other documents depending on the destination market and applicable regulations.

Important Safety & Medical Information

Trastuzumab can cause serious adverse reactions, including cardiac dysfunction and infusion-related reactions. The FDA prescribing information includes a boxed warning concerning cardiomyopathy and embryo-fetal toxicity. Appropriate medical assessment and monitoring are therefore required during treatment.

This page is intended for product and procurement information and does not replace professional medical advice, prescribing information, or the regulatory requirements of the destination country. Trastuzumab should be used only under the supervision of a qualified healthcare professional.

Trastuzumab 440 mg Injection Procurement Enquiry

For international pharmaceutical sourcing enquiries, contact Cordium Pharmaceuticals Pvt Ltd